A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• •1. Patients with a confirmed diagnosis of Multiple Myeloma, Chronic Lymphocytic Leukaemia, or B-cell Non-Hodgkin's Lymphoma, who have had at least two prior standard treatment regimens and are without established therapeutic alternatives.
• •2. Signed IEC-approved informed consent
• •3. ECOG performance status of 0, 1 or 2;
• •4. Life expectancy of at least 3 months;
• •5. Adequate haematologic status, liver function and renal function
• •6. Patients of reproductive potential must agree to follow accepted birth control methods during the study